The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
“ I still think if drilling wasn’t going well then that video with a rather happy relaxed and happy chappy wouldn’t be tweeted. ”
Anyone remember the happy and relaxed videos with David Minchin telling us that he could see the helium bubbles? That went well, didn’t it?
Here’s the link https://x.com/qbtofficial256/status/1717087050367746245?s=61&t=C7iN6IQxKWDmhfIN-tKwdg
You do realise that LSE has a tab per share where you can check short positions?
https://www.lse.co.uk/ShareShortPositions.html?shareprice=RR.&share=Rolls-Royce
Apparently nothing to see here.
I’m suddenly back in love with my portfolio this weekend. Hopefully this one sustains momentum next week!
Loving the look of my portfolio this weekend. Chose GCAT, because it’s not just a miner but a producer.
Https://gsiexchange.com/wp-content/uploads/2020/12/Klaus-Schwab.png
Don’t worry, your future leader already has his Star Trek-inspired costume ready for the alien invasion. But what if they take on human form? M if Avacta DX had any foresight, they’d be developing an LFT to identify reptilians.
By the way, what ARE they working on?
The Biden administration's new biomedical research agency is providing $24 million for research leveraging an mRNA platform to train the immune system to fight cancer and other diseases, officials told Axios first.
https://www.axios.com/2023/08/23/biden-cancer-research-mrna
Never heard of “lockstep”?
But seriously, you ignore this huge long-term declaration of intent by our horrendously corrupt Gov? How can Avacta monetise their anti-cancer offering with this going on in the background?
Follow the money. They want people to take cancer jabs developed by Moderna to justify their 10-year vaccine production agreement.
The UK government has refused to reveal how much it has spent on a 10-year deal with the US pharmaceutical company Moderna—despite growing public interest in the UK’s vaccine manufacturing capability.
Agreed in December, the £1 billion deal includes plans for a vaccine research and manufacturing facility with the capacity to produce up to 250 million vaccines a year, with the first due to be made in 2025.
https://www.gov.uk/government/news/uk-cements-10-year-partnership-with-moderna-in-major-boost-for-vaccines-and-research
https://www.theguardian.com/society/2023/apr/07/cancer-and-heart-disease-vaccines-ready-by-end-of-the-decade
Noting a 200%+ increase for Aptamer Group on the announcement that they are to develop an LFT for early detection of Alzheimer’s Disease…
Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, and Neuro-Bio, an Oxford-based biotechnology company with a therapeutic focus on neurodegenerative disease, announce success in the development of Optimer binders to enable a lateral flow test for the early diagnosis of Alzheimer's disease.
Come on Sir Al, what are those little affimers detecting that’s monetisable? Surely it can’t be too difficult to develop a test to reveal all the aluminium and glyphosate particles that we’re breathing in daily?
Https://www.dailymail.co.uk/home/index.html
The next great medical stitch up to persuade us to accept yet more jabs.